Polaris Group Announces Issuance of New Patent Protecting Lead Product Candidate ADI‑PEG 20

SAN DIEGO, May 16, 2016 — Polaris Group announced today that it has received notification that the United States Patent and Trademark Office will issue to Polaris Group a new utility patent that will contain claims protecting the pharmaceutical composition of ADI‑PEG 20 which Polaris Group plans to commercialize upon receiving regulatory approval, as well as claims covering therapeutic use of the compositions of ADI‑PEG 20 for the treatment of a variety of cancer indications.  The patent number is 9,333,268 with an issue date of May 10, 2016.  The term of the patent is expected to extend to May 30, 2032.

About ADI‑PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed.  Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group, a multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. Polaris Group is investigating ADI‑PEG 20 as a treatment for a number of cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, pancreatic cancer and hepatocellular carcinoma. In addition to the ADI‑PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com.

CONTACT: Max Barker, (858) 452-6688, ext. 128, mbarker@polarispharma.com